Articles - Page 16 of 96 - Drugs in Context

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors

Darren MC Poon, Kuen Chan, Angus Kwong-Chuen Leung, Brian Ng, Foon-Yiu Cheung, Steven Wai-Kwan Siu, Hong Kong Society of Uro-Oncology

Article Type

Original Research

Published

21 Jun 2023

In this study, the authors investigated the toxicity and efficacy of cabozantinib in Chinese patients who progressed on VEGFR TKIs and/or ICIs in real-life clinical practice.

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2– breast cancer treated with CDK4/6 inhibitors and endocrine therapy

Barbara Tagliaferri, Ludovica Mollica, Raffella Palumbo, Claudia Leli, Alberto Malovini, Matteo Terzaghi, Erica Quaquarini, Cristina Teragni, Stefano Maccarone, Andrea Premoli, Federico Sottotetti

Article Type

Original Research

Published

20 Jun 2023

This real-life study investigated the link between clinical complexity and quality of life of patients with HR+/HER2– advanced breast cancer treated with CDK4/6 inhibitors.

Treatment of the common cold with herbs used in Ayurveda and Jamu: monograph review and the science of ginger, liquorice, turmeric and peppermint

Retno S Wardani, Natalie Schellack, Tamlyn Govender, Abhay N Dhulap, Prapti Utami, Vinod Malve, Yong Chiat Wong

Article Type

Review

Published

14 Jun 2023

This review aims to provide a better understanding of the traditional and modern perspectives on some of the herbal ingredients (ginger, liquorice, turmeric and peppermint) putatively used for common cold symptom management.

Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report

Yeong Yeh Lee, Vincent Tee

Article Type

Case Report

Published

13 Jun 2023

This report discusses silymarin in a patient with diabetes and grade II non-alcoholic steatohepatitis, confirming significant hepatoprotective effects as shown by the reduction of liver enzyme activities.

Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms

Mikhail Kostinov, Oksana Svitich, Alexander Chuchalin, Natalya Abramova, Valery Osiptsov, Ekaterina Khromova, Dmitry Pakhomov, Vitaly Tatevosov, Anna Vlasenko, Vilia Gainitdinova, Kirill Mashilov, Nadezhda Kryukova, Irina Baranova, Anton Kostinov

Article Type

Original Research

Published

12 Jun 2023

This article aims to assess the secretion of SIgA in the nasal and pharyngeal compartments and saliva of patients with COVID-19 and to investigate the possibility and efficiency of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms.